CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colomar, M.
Right arrow Articles by Espel, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colomar, M.
Right arrow Articles by Espel, E.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, September 2003, p. 751-756, Vol. 10, No. 5
1071-412X/03/$08.00+0     DOI: 10.1128/CDLI.10.5.751-756.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Neutralization of Measles Virus Infectivity and Antibody-Dependent Cell-Mediated Cytotoxicity Activity against an Epstein-Barr Virus-Infected Cell Line by Intravenous Administration of Immunoglobulin G

MariCarmen Colomar,1 Irene Puga,1 Maite López,2 Marta Massot,2 Juan I. Jorquera,2 Manuel Reina,3,4 Senen Vilaró,3,4 and Enric Espel1*

Departament de Fisiologia,1 Departament de Biologia Cellular,3 Facultat de Biologia, and Advancell, Parc Científic, Universitat de Barcelona, 08028 Barcelona,4 Instituto Grífols S.A., Parets, Spain2

Received 9 December 2002/ Returned for modification 8 February 2003/ Accepted 8 June 2003

Patients with antibody deficiency disorders are highly susceptible to microbial infections. Intravenous (i.v.) immunoglobulin concentrates were originally developed as replacement therapy for such patients. The present study assesses the measles virus neutralizing antibody titers and the antibody-dependent cell-mediated cytotoxicity (ADCC) capacities against Epstein-Barr virus (EBV)-infected cells of immunoglobulin G (IgG) preparations produced for i.v. use (i.v. IgG). The level of neutralizing antibodies against measles virus was determined by a syncytium neutralization test with Vero cells as targets. The measles virus neutralizing antibody titers of the i.v. IgG preparations were >3 x 102 and were an average of 1.0 log higher than the titers in pooled plasma from healthy subjects. The two IgG preparations tested showed similar ADCC activities against EBV-infected Raji cells, being active at concentrations of 3 mg/ml or higher. i.v. IgG bound to Raji cells but not to the EBV-negative Ramos cells, as evaluated by flow cytometry. Our in vitro findings may provide further support for the use of i.v. IgG for the prevention and treatment of infections caused by specific viral pathogens.

* Corresponding author. Mailing address: Department of Fisiologia, Facultat Biologia, Diagonal 645, 08028 Barcelona, Spain. Phone: 34 93 402 15 27. Fax: 34 93 411 03 58. E-mail: eespel{at}ub.edu.

Clinical and Diagnostic Laboratory Immunology, September 2003, p. 751-756, Vol. 10, No. 5
1071-412X/03/$08.00+0     DOI: 10.1128/CDLI.10.5.751-756.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2003 by the American Society for Microbiology. All rights reserved.